References
- Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. 2019. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 10(5):1299–1306.
- Brown K, Mendell J, Ohwada S, Hsu C, He L, Warren V, Dishy V, Zahir H. 2018. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: results from phase 1 studies. Pharmacol Res Perspect. 6(5):e00418.
- Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, Kai K, Kitano Y. 2018. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 365(3):573–582.
- Jansen M, Warrington S, Dishy V, Ohwada S, Johnson L, Brown K, Ishizuka H. 2018. A randomized, placebo-controlled, double-blind study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeated doses of mirogabalin in healthy Asian volunteers. Clin Pharmacol Drug Dev. 7(6):661–669.
- Kato J, Matsui N, Kakehi Y, Murayama E, Ohwada S, Sugihara M. 2019. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 160(5):1175–1185.
- Kitano Y, Kai K, Yamamura N, Yoshiba S, Kuroha M. 2019. Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige® tablets 2.5 mg·5 mg·10 mg·15 mg). Nihon Yakurigaku Zasshi. 154(6):352–361.
- Lin HJ, Los EL, Ulm HE, Duggan ED. 1987. Urinary excretion kinetics of famotidine in rats. Drug Metab Dispos. 15(2):212–216.
- Prueksaritanont T, Hochman HJ, Meng Y, Pudvah TN, Barrish A, Ma B, Yamazaki M, Fernandez-Metzler C, Lin HJ. 2004. Renal elimination of a novel and potent alphavbeta3 integrin antagonist in animals. Xenobiotica. 34(11–12):1059–1074.
- Tachibana M, Yamamura N, Atiee GJ, Hsu C, Warren V, He L, Dishy V, Zahir H. 2018. Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: a phase 1, randomized, open-label, drug-drug interaction study. Br J Clin Pharmacol. 84(10):2317–2324.
- Yamamura N, Mendel-Harary J, Brown K, Uchiyama M, Urasaki Y, Takahashi M, Warren V, Vashi V. 2021. Metabolism, excretion, and pharmacokinetics of [14C]mirogabalin, a novel α2δ ligand, in healthy volunteers following oral administration. Xenobiotica. 51(5):549–563.